Increasing clinical tests of trademarked products by key players is expected to drive growth of the market during the forecast period. In June 2019, Stryker Corporation announced that 33,000 patients were treated with company’s LATERA absorbable nasal implant device. The device is used to support the lateral nasal cartilage and address the symptoms of NVC, which help the patients to breathe better.
Key players are involved in various business strategies such as product launch to gain the competitive edge in the market. In April 2018, Intersect ENT announced the launch of its SINUVA sinus implant, which is a novel in-office treatment option for recurrent nasal polyps. It is a clinically proven treatment for patients suffering from nose, throat, and ear conditions.